Unlock instant, AI-driven research and patent intelligence for your innovation.

Sustained-release therapeutic agent for hypertension and renal dysfunction

A kidney function and slow-release technology, applied in the direction of organic active ingredients, cardiovascular system diseases, skin care preparations, etc., can solve problems such as ignorance, and achieve a strong therapeutic effect

Inactive Publication Date: 2013-03-06
TEIJIN PHARMA CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is not known that administration in a sustained release manner significantly enhances its effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained-release therapeutic agent for hypertension and renal dysfunction
  • Sustained-release therapeutic agent for hypertension and renal dysfunction
  • Sustained-release therapeutic agent for hypertension and renal dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] The effects of immediate-release and sustained-release administration of febuxostat in a model of naturally occurring hypertension were confirmed.

[0063] A 12-week-old male SHR (Spontaneously Hypertensive Rat: spontaneously hypertensive rat) was used as a sample after being quarantined for more than 1 week. From the age of 13 weeks, blood pressure measurement was carried out by Tail-Cuff sphygmomanometer (BP-2000, Visitech systems, Napa Place, NC, USA) for 2 weeks. After the adaptation, the blood pressure was measured at the age of 15 weeks, and the samples were divided into 3 groups (10 rats in each group) so that there was no deviation in the systolic blood pressure, and then the administration was started. The control group of the first group was given tap water. Febuxostat was given to the drinking water of group 2. Febuxostat was administered orally compulsorily to Group 3.

[0064] Drinking water administration was performed by allowing them to freely drink a...

Embodiment 2

[0069] The effects of immediate-release and sustained-release administration of febuxostat in adriamycin-induced nephropathy mouse models were confirmed. The doxorubicin-induced nephropathy model is known as a renal insufficiency model in which glomerular epithelial cells are damaged and proteinuria is exhibited.

[0070] Seven-week-old male BALB / cAnNCrlCrlj mice were quarantined for more than one week and used as specimens.

[0071] Urine storage was carried out for 24 hours at the age of 8 weeks, and the amount of albumin in the urine obtained from the storage was measured by the ELISA method. After the samples were divided into three groups so that there was no variation in the amount of urinary albumin excretion, the administration was started. The control group of the first group was given tap water. Febuxostat was given to the drinking water of group 2. Febuxostat was administered orally compulsorily to Group 3.

[0072] Drinking water administration was performed by...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a therapeutic agent or prophylactic for hypertension or normal high blood pressure and renal dysfunction that is more effective than conventional drugs. Specifically disclosed is a sustained-release pharmaceutical composition for the treatment or prevention of hypertension or normal high blood pressure and renal dysfunction and which contains a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active component.

Description

technical field [0001] The present invention relates to a sustained-release pharmaceutical composition for the treatment or prevention of hypertension or hypertensive normotensive disease, and a treatment method or prevention method using the same. [0002] Furthermore, the present invention relates to a sustained-release pharmaceutical composition for the treatment or prevention of renal insufficiency, and a treatment method or prevention method using the same. Background technique [0003] Xanthine oxidase inhibitors have the effect of reducing the uric acid value in the blood by inhibiting uric acid synthesis, improving hyperuricemia and ventilation. [0004] On the other hand, hyperuricemia has been pointed out to be related to hypertension, and it has actually been reported that hyperuricemia is a risk factor for the onset of hypertension (Non-Patent Document 1). Therefore, xanthine oxidase inhibitors that improve hyperuricemia may become therapeutic drugs for hyperten...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/426A61P9/12A61P13/12A61P19/06
CPCA61K31/426A61P9/00A61P9/12A61P13/12A61P19/06A61P43/00A61Q19/06
Inventor 白仓尚M.田村高桥良昌桑原一平
Owner TEIJIN PHARMA CO LTD